Prostate Cancer
🌏 NMPANMPA news and analysis for pharmaceutical BD, investment, and market access
Global prostate cancer market intelligence for pharma BD, investors & analysts. Track drug development, clinical trials, and regulatory approvals.
Showing 1–4 of 4 articles
Quick answer
NovaPharmaNews Prostate Cancer hub for NMPA covers 4 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
Minghui and Qilu Pharmaceutical Unveil Promising MHB088C Data in mCRPC at ASCO 2026
Novartis Strengthens Prostate Cancer Treatment with Pluvicto
TLX597-Tx PSMA Radioligand Therapy Shows Promise in OPTIMAL-PSMA Trial for Early-Stage Prostate Cancer
Radioligand Therapies for Prostate Cancer: Market Access and Clinical Insights in APAC
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.